Google
CRVS Stock Price & Analysis — Corvus Pharmaceuticals Inc (Healthcare >> Biotechnology)
CRVS FAQ
What is CRVS's ROE?
Corvus Pharmaceuticals Inc reports a Return on Equity (ROE) of -18.35%.
What is CRVS's dividend yield?
Corvus Pharmaceuticals Inc offers a dividend yield of 0.00%.
What is CRVS's Quality Score?
Our AI rates CRVS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CRVS?
Our AI Timing Score for CRVS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CRVS belong to?
Corvus Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CRVS AI Analysis Summary
Our AI summary for CRVS: Corvus Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -18.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 13.92
Price
0.55
(4.11%)
Day Change
|
|
|---|
CRVS, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 13.92 |
| PBV / Sector |
4.67 / 44,022.72
|
| Earning Per Share | -0.55 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
14.23 M
GREAT
|
| Average 1W Daily Value |
9.77 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:02 |
| Symbol | CRVS |
| Name | CORVUS PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 84.09 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,124.29 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 900 4520
Website: https://www.corvuspharma.com
Sector: Healthcare >> Biotechnology
Description: Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap